**COVID-19 Delta Update - and the threat from emerging variants**

**NeoHack Life Sciences, Dallas, Texas August 25, 2021**

We are excited to share that our vision to help save more lives in the COVID fight has been advanced.

Neo-19TM (OTC) reduces bacterial/viral coughing with homeostatic, patent-pending cough lozenge. Millions of people who have already contracted COVID-19 could have benefited from additional or alternative treatment methods in order to fight the onslaught of symptoms identified as the cytokine storm. Coughing is one of the most severe symptoms of COVID-19, and maintaining clear air passageways is paramount. Neo-19 directly addresses this, in a new and efficacious way that will be accessible over-the-counter. Neo-19TM also works against other viral and bacterial symptoms.

The first trial run of our Neo-19TM product was completed earlier this month, and it validated the continuation of formulating herbal actives with our patent pending compositions. Our approach relies on a slowly dissolving lozenge to deliver components to the body, and our research shows that these components can be effective to fight the COVID-induced cytokine storm.

The following extract published by Harvard University succinctly explains that the cytokine storm “*may cause more harm than the coronavirus itself”*:

**“What are cytokine storms and what do they have to do with COVID-19?**

**A cytokine storm is an overreaction of the body's immune system. In some people with COVID-19, the immune system releases immune messengers, called cytokines, into the bloodstream out of proportion to the threat or long after the virus is no longer a threat.**

**When this happens, the immune system attacks the body's own tissues, potentially causing significant harm. A cytokine storm triggers an exaggerated inflammatory response that may damage the liver, blood vessels, kidneys, and lungs, and increase formation of blood clots throughout the body. Ultimately, the cytokine storm may cause more harm than the coronavirus itself”.**

**Harvard University (May 17, 2021)** <https://www.health.harvard.edu/diseases-and-conditions/covid-19-basics>

The cytokine storm can overwhelm the body’s defenses, and the recent emergence of the Delta through Lambda variants is in many cases contributing to the surge in hospitalization and resultant use of respirators.

NeoHack’s next step in the development of Neo-19TM is to perform a full-scale validation test on its ability to stop the cytokine storm. To accomplish this goal, NeoHack will be raising capital to ensure the production of a test-ready batch of Neo-19TM doses.

Inquiries into this effort are welcome. Please contact any member of the NeoHack Senior Officer team.

Ron Butler, Chief Executive Officer rb@neohacksciences.com

Dr. Dale Brown, PhD, Chief Science Officer db@neohacksciences.com

Niklas James, Chief Development Officer nj@neohacksciences.com